Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial


Zanchetti A., Liu L., Mancia G., Parati G., Grassi G., Stramba-Badiale M., et al.

JOURNAL OF HYPERTENSION, cilt.32, ss.1888-1897, 2014 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 32 Konu: 9
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1097/hjh.0000000000000254
  • Dergi Adı: JOURNAL OF HYPERTENSION
  • Sayfa Sayısı: ss.1888-1897

Özet

Background and objectives: The SBP values to be achieved by antihypertensive therapy in order to maximize reduction of cardiovascular outcomes are unknown; neither is it clear whether in patients with a previous cardiovascular event, the optimal values are lower than in the low-to-moderate risk hypertensive patients, or a more cautious blood pressure (BP) reduction should be obtained. Because of the uncertainty whether 'the lower the better' or the 'J-curve' hypothesis is correct, the European Society of Hypertension and the Chinese Hypertension League have promoted a randomized trial comparing antihypertensive treatment strategies aiming at three different SBP targets in hypertensive patients with a recent stroke or transient ischaemic attack. As the optimal level of low-density lipoprotein cholesterol (LDL-C) level is also unknown in these patients, LDL-C-lowering has been included in the design.